Core Points - The Shanghai Cathay Biotech Co., Ltd. is holding its second extraordinary general meeting of shareholders in 2025 on August 18 [1][2] - The meeting aims to ensure the legal rights of all shareholders and maintain order and efficiency during the proceedings [2][3] Meeting Procedures - Shareholders must verify their identity upon arrival and sign in to confirm their attendance [2][3] - Attendees are required to return their shareholder certificates and meeting folders after the meeting [3] - Shareholders have the right to speak and vote during the meeting, but must adhere to the agenda and obtain permission from the meeting host to speak [3][5] Voting and Agenda - The network voting will take place on August 18, 2025, during specified trading hours [5] - The agenda includes the announcement of the meeting's commencement, introduction of attendees, and the review of several proposals [9] - Key proposals include the cancellation of the supervisory board and amendments to the company's articles of association [5][8] Proposals Overview - Proposal 1: Cancellation of the supervisory board and modification of the company's articles to enhance governance structure [5][6] - Proposal 2: Amendments to the company's rules for shareholder meetings and other governance documents to ensure compliance with relevant laws [8] - Proposal 3: Election of non-independent directors for the third board, with candidates nominated for a three-year term [11][12] - Proposal 4: Election of independent directors for the third board, with candidates already approved by the Shanghai Stock Exchange [11][12]

上海凯赛生物技术股份有限公司 2025 年第二次临时股东大会会议资料 证券代码：688065 证券简称：凯赛生物 上海凯赛生物技术股份有限公司 上海凯赛生物技术股份有限公司 2025 年第二次临时股东大会会议资料 上海凯赛生物技术股份有限公司 地址：中国（上海）自由贸易试验区蔡伦路 1690 号 5 幢 邮编：201203 电话：86-21-50801916 传真：86-21-50801386 网站：http://www.cathaybiotech.com 2025 年第二次临时股东大会会议资料 中国·上海 二〇二五年八月十八日 上海凯赛生物技术股份有限公司 2025 年第二次临时股东大会会议资料 目 录 | 上海凯赛生物技术股份有限公司 2025 年第二次临时股东大会会议须知 1 | | --- | | 上海凯赛生物技术股份有限公司 2025 年第二次临时股东大会议程 3 | | 议案一：关于取消公司监事会并修改公司章程的议案 4 | | 议案二：关于修改公司《股东会议事规则》等规章制度的议案 5 | | 议案三：关于选举公司第三届董事会非独立董事的议案 6 | | 议案四：关于选举公司第三届董事会独立董事 ...

为更好地服务广大中小投资者，确保有投票意愿的中小投资者能够及时参会、 及时投票，公司拟使用上证所信息网络有限公司（以下简称"上证信息"）提供 的股东大会提醒服务，委托上证信息通过智能短信等形式，根据股权登记日的股 东名册主动提醒股东参会投票，向每一位投资者主动推送股东大会参会邀请、议 案情况等信息。投资者在收到智能短信后，可根据《上市公司股东会网络投票一 键通服务用户使用手册》（下载链接：https://vote.sseinfo.com/i/yjt_help.pdf）的 提示步骤直接投票，如遇拥堵等情况，仍可通过原有的交易系统投票平台和互联 网投票平台进行投票。 若广大投资者对本次服务有任何意见或建议，可通过邮件、投资者热线等方 式向公司反馈，感谢广大投资者对公司的关注与支持。 特此公告。 证券代码：688065 证券简称：凯赛生物 公告编号：2025-040 上海凯赛生物技术股份有限公司 关于股东大会开设网络投票提示服务的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海凯赛生物技术股份有限公司（以下简称"公司"）拟 ...

Investment Rating - The report maintains a rating of "Outperform" for the new materials sector [1]. Core Insights - The new materials sector has experienced a decline, with the new materials index falling by 2.34%, underperforming the ChiNext index by 1.59% [2]. - The global humanoid robot market is projected to grow from $2.16 billion in 2023 to $32.4 billion by 2029, with a compound annual growth rate (CAGR) of 57% [5]. - The domestic PEEK material market is expected to reach 2.1 billion yuan by 2025, reflecting a year-on-year growth of 10.53% [5]. Market Performance - The new materials sector saw a decline this week, with the new materials index down by 2.34% [2]. - Over the past five trading days, the synthetic biology index increased by 2.06%, while semiconductor materials decreased by 0.65% and battery chemicals fell by 3.84% [18]. - The overall market performance for the new materials sector has been mixed, with various sub-sectors showing different trends [19]. Price Tracking - Amino acids such as valine, arginine, and tryptophan have seen price changes of -1.05%, -1.64%, and -2.15% respectively [3]. - Prices for biodegradable materials like PLA and PBS remained stable, while PBAT was priced at 9,850 yuan per ton [3]. - The price of industrial gases and electronic chemicals has also remained unchanged, indicating stability in these segments [3]. Investment Recommendations - The report suggests focusing on companies involved in PEEK material production and modification, such as Zhongxin Fluorine Materials and Zhongyan Co., as well as functional protective casing manufacturers like Jundida [5][6]. - The upcoming World Robot Conference is highlighted as a key event to watch for advancements in humanoid robot materials [5].

Group 1 - The company will hold its second extraordinary general meeting of shareholders in 2025 on August 18 at 14:00 in Shanghai [2][4] - The voting will be conducted through both on-site and online methods, with specific time slots for each [4][6] - Shareholders must register to attend the meeting, with detailed requirements for both individual and corporate shareholders [10][12] Group 2 - The meeting will review several proposals, including the election of the third board of directors, which will consist of 5 non-independent directors, 3 independent directors, and 1 employee representative director [24][26] - The election will utilize a cumulative voting system, allowing shareholders to allocate their votes among candidates [9][22] - The current board will continue to operate until the new board is elected [27] Group 3 - The company has initiated a share repurchase program, with a total budget between RMB 10 million and RMB 20 million, and a maximum repurchase price of RMB 67 per share [38][39] - As of July 31, 2025, the company has repurchased 230,366 shares, representing 0.0319% of the total share capital, at a total cost of approximately RMB 10.5 million [40] Group 4 - The company has decided to abolish its supervisory board, transferring its responsibilities to the audit committee of the board of directors [43] - Amendments to the company's articles of association and related internal management systems will be made accordingly [45]

Core Points - The document outlines the independent director system of Shanghai Kaisa Biotechnology Co., Ltd, aiming to enhance corporate governance and protect the interests of minority shareholders [1][2][3] Chapter Summaries Chapter 1: General Principles - The independent director system is established to improve the governance structure of the company and ensure the protection of minority shareholders' rights [1] - Independent directors must not hold any other positions within the company and should have no direct or indirect interests that could affect their independent judgment [1] Chapter 2: Qualifications for Independent Directors - Basic qualifications for independent directors include legal eligibility, independence, knowledge of company operations, and relevant work experience [2] - Candidates must not have any significant negative records in the past 36 months related to securities violations or other misconduct [2] Chapter 3: Independence of Directors - Certain individuals are prohibited from serving as independent directors, including those with significant shareholdings or familial ties to major shareholders [3][4] Chapter 4: Nomination, Election, and Replacement of Independent Directors - Independent director candidates can be proposed by the board or shareholders holding more than 1% of shares, requiring majority approval at the shareholders' meeting [5] - The company must disclose detailed information about independent director candidates before the shareholders' meeting [6][7] Chapter 5: Responsibilities and Duties of Independent Directors - Independent directors are responsible for participating in board decisions, supervising potential conflicts of interest, and providing professional advice [8][9] - They have the authority to hire external consultants for audits or inquiries into specific matters [9][10] Chapter 6: Special Meetings of Independent Directors - The company must hold regular or ad-hoc meetings exclusively for independent directors to discuss relevant issues [12][13] Chapter 7: Obligations of Independent Directors - Independent directors must maintain independence and report any conflicts of interest or issues affecting their ability to perform their duties [14][15] - They are required to keep detailed records of their activities and interactions related to their responsibilities [15][16] Chapter 8: Rights of Independent Directors and Company Obligations - The company must ensure independent directors have equal access to information and necessary resources to perform their duties [16][17] - Independent directors are entitled to reasonable compensation, which must be disclosed in the company's annual report [17] Chapter 9: Supplementary Provisions - The independent director system must comply with national laws and regulations, and any conflicts with future regulations will be resolved in favor of the latter [18][19]

Core Points - The document outlines the information disclosure system of Shanghai Kasei Biotechnology Co., Ltd, aiming to enhance the quality and standardization of information disclosure, ensuring that information is disclosed truthfully, accurately, completely, timely, and fairly to protect the rights of the company, shareholders, and other stakeholders [1][2][3]. Group 1: General Principles - The information disclosure obligations apply to the company, its subsidiaries, and major shareholders holding more than 5% of shares, including directors, senior management, and relevant departments [2][3]. - Information disclosure must adhere to principles of openness, fairness, and equal treatment of all shareholders, prohibiting selective disclosure [3][4]. Group 2: Disclosure Obligations - Information that may significantly impact the trading price of the company's stock must be disclosed in a timely manner, including both regular and temporary reports [3][11]. - The company must ensure that disclosed information is truthful, accurate, complete, and clear, avoiding misleading statements or omissions [4][5]. Group 3: Reporting Procedures - Regular reports include annual, semi-annual, and quarterly reports, which must be disclosed within specified timeframes after the end of the respective periods [8][9]. - Temporary reports must be issued immediately upon the occurrence of significant events that could affect stock prices, detailing the event's cause, current status, and potential impact [11][12]. Group 4: Media and Publication - Information must be disclosed on the Shanghai Stock Exchange website and other approved media, ensuring that the public has access to the information [7][55]. - The company may also publish information on its website and other public media, but not before the designated disclosures [25][26]. Group 5: Confidentiality and Penalties - Individuals with access to undisclosed information must maintain confidentiality and are prohibited from trading the company's stock based on insider information [26][27]. - Violations of disclosure regulations may result in penalties, including disciplinary actions against responsible individuals and potential legal consequences [27][28].

Core Points - The company, Shanghai Kaisa Biotechnology Co., Ltd., has announced a share repurchase plan proposed by its original controlling shareholder, Cathay Industrial Biotech Ltd. [1] - The repurchase period is set from October 21, 2024, to October 20, 2025, with an expected repurchase amount between 10 million yuan and 20 million yuan [1] - The repurchased shares will be used for employee stock ownership plans or equity incentives [1] Summary of Share Repurchase Details - The total amount for the share repurchase is not less than 10 million yuan and not more than 20 million yuan, with a maximum repurchase price of 67 yuan per share [1] - As of the latest update, the company has repurchased a total of 230,366 shares, which accounts for 0.0319% of the total share capital of 721,289,794 shares [1] - The total amount spent on the repurchase so far is approximately 10,497,716.71 yuan, with the highest purchase price being 53.40 yuan per share and the lowest being 44.08 yuan per share [1][2]

Core Points - The company, Cathay Biotech, is holding its second extraordinary general meeting of shareholders on August 18, 2025, to discuss various proposals [4][6]. - The voting will be conducted through both on-site and online methods, with specific time slots allocated for each [4][5]. - The meeting will include the election of a non-independent director, Mr. Xiucai Liu, and the approval of the company's remuneration management system for directors and senior management [2][9]. Meeting Details - The general meeting will take place at 14:00 on August 18, 2025, at the company's office located in Shanghai [4]. - Shareholders must register to attend the meeting, with specific documentation required for both individual and corporate shareholders [6][7]. - The voting process will allow shareholders to cast their votes either through the Shanghai Stock Exchange's online voting system or in person [5][6]. Voting Procedures - The voting will include both cumulative and non-cumulative voting methods, with detailed instructions provided for shareholders [10][11]. - Shareholders will have the right to vote based on the number of shares they hold, with specific rules regarding the validity of votes [10][11]. - The company emphasizes the importance of proper registration and voting procedures to ensure a smooth meeting [5][7].

Core Viewpoint - Shanghai Kaisa Biotechnology Co., Ltd. has decided to abolish its supervisory board and amend its articles of association, with the audit committee of the board taking over the supervisory functions [1][2]. Summary by Sections Cancellation of Supervisory Board - The company will no longer have a supervisory board, as per the relevant laws and regulations, with the audit committee of the board assuming the supervisory responsibilities [2][3]. - The existing rules regarding the supervisory board will be abolished, and the company will continue to ensure compliance and oversight until the shareholders' meeting approves this change [2]. Amendments to Articles of Association - The amendments aim to enhance the corporate governance structure in line with the requirements for companies listed on the Sci-Tech Innovation Board [3]. - Specific changes include the redefinition of the roles and responsibilities of the board and the legal representative [4][5]. - The articles will now reflect that the legal representative is the chairman of the board, and the company will bear civil liability for actions taken by the legal representative [4][5]. Shareholder Rights and Responsibilities - Shareholders will continue to have rights to dividends and other benefits proportional to their shareholdings [12][13]. - The articles stipulate that shareholders must comply with laws and the company's regulations, and they cannot abuse their rights to harm the company or other shareholders [39][40]. Financial Assistance and Guarantees - The company must seek approval from the shareholders' meeting for any financial assistance or guarantees exceeding certain thresholds, ensuring transparency and accountability [20][21]. - Specific conditions under which the company can provide financial assistance or guarantees are outlined, including limits based on the company's audited net assets [20][21].